Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Data Tool: How to Design an EHR Algorithm to Identify SLE Patients

Arthritis Care & Research  |  

Electronic health records enable researchers to access significant amounts of patient data, but identifying subjects with a specific condition can be difficult. In a recent study, researchers successfully designed three algorithms to identify patients with SLE, incorporating multiple counts of the ICD-9 code, laboratory testing, medication data and keywords. In the future, these algorithms may successfully transfer to other systems to aid research…

Mindfulness-Based Stress Reduction Only Slightly Improves Low Back Pain

Will Boggs, MD  |  

(Reuters Health)—Mindfulness-based stress reduction programs (MSBR) appear to improve low back pain only slightly, and only temporarily, a review of previous research suggests. These programs combine meditation while sitting and walking, yoga, focusing attention on different parts of the body and incorporation of mindfulness/awareness into everyday life. Earlier studies found MBSR to be helpful for…

Tofacitinib Treatment May Improve Nail Psoriasis

Rita Buckley  |  

NEW YORK (Reuters Health)—The oral Janus kinase (JAK) inhibitor tofacitinib appears to improve moderate to severe nail psoriasis, according to a new study. “Nails are hard to treat in psoriasis and we need better treatments,” says Dr. Luis Garza, a dermatologist at Johns Hopkins School of Medicine in Baltimore, who was not involved in the research….

EMA Panel Recommends Nod for Sanofi, Regeneron’s Arthritis Drug

Reuters Staff  |  

(Reuters)—A European Medicines Agency panel said on Friday it recommended granting marketing approval to Sanofi and Regeneron’s experimental drug to treat rheumatoid arthritis (RA). The Committee for Medicinal Products for Human Use gave a positive opinion on the drug, sarilumab (Kevzara), citing its ability to reduce the signs and symptoms of RA. Sarilumab, the active…

Valeant Prices Psoriasis Treatment at $3,500 Per Month

Reuters Staff  |  

(Reuters)—Canadian drug maker Valeant Pharmaceuticals International Inc. said it had priced its recently approved plaque psoriasis treatment at $3,500 per month, ahead of an expected U.S. launch in the second half of 2017. Brodalumab (Siliq) is the lowest priced injectable biologic psoriasis treatment currently on the market, Valeant says. Drugmakers are facing intense criticism from…

Tocilizumab Effectively Treats Early RA for Up to Two Years

Marilynn Larkin  |  

NEW YORK (Reuters Health)—Patients with early rheumatoid arthritis (RA) treated with IV tocilizumab alone or with methotrexate maintained clinical benefits during their second year of treatment, researchers say. Sophie Dimonaco of Roche Products Ltd. in Welwyn Garden City, UK and colleagues sought to determine whether the efficacy and safety of IV tocilizumab, as demonstrated in…